Earnings Results
Estrella Immunopharma (NASDAQ:ESLA) reported quarterly earnings results on November 16, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.17, missing the consensus estimate of $-0.08 by $0.09 per share. Revenue came in at , meeting the estimate of .
Company Overview
Estrella Immunopharma's stock moved following the earnings release. The stock currently trades at $0.51 with a market capitalization of $70.2M.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 112% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Estrella Immunopharma should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
Estrella Immunopharma Earnings History
| Quarter | EPS Actual | EPS Est. | Surprise |
| Q3 (Nov 2026) | $-0.17 | $-0.08 | -112.5% |
| Q2 (Aug 2026) | $-0.05 | $-0.09 | +44.4% |
| Q1 (May 2026) | $-0.05 | $-0.12 | +58.3% |
| Q4 (Mar 2026) | $-0.01 | $-0.12 | +91.7% |
Related Tools: Earnings Calendar | View ESLA Stock Page
Frequently Asked Questions
When does Estrella Immunopharma report earnings?
Check the latest earnings dates on our ESLA earnings page or the Earnings Calendar.
Did ESLA beat earnings estimates?
See the full Q3 results including EPS actual vs estimate on our ESLA earnings page.